- Newborn screening is a vital process that helps detect congenital disorders early, allowing for timely interventions that can significantly improve health outcomes for infants. It includes tests for metabolic, genetic, and hearing disorders, typically conducted shortly after birth
- The newborn screening market is experiencing steady growth, driven by rising awareness of the importance of early diagnosis, increased government mandates and healthcare initiatives, advancements in screening technologies, and the growing prevalence of congenital disorder
- North America is expected to dominate the newborn screening market with a share of 48.8%, due to the widespread implementation of universal screening programs, high healthcare spending, and a strong regulatory framework supporting early diagnosis of congenital disorders
- Asia-Pacific is expected to be the fastest growing region in the newborn screening market during the forecast period with a share of 33.40%, due to increasing awareness of early diagnosis, expansion of national screening programs, and government support in emerging economies
- Instruments segment is expected to dominate the market with a market share of 76.41% due to increasing adoption of advanced screening technologies such as tandem mass spectrometry (MS/MS), improved automation in laboratories, and the rising demand for high-throughput and accurate diagnostic tools that enable early detection of a wide range of congenital disorders
